Tom Woiwode, Ph.D.

has been working with Versant since 2002, and has served in both operational and investment roles during that time.

Tom was the start-up CBO for Amira (sale), Synosia (sale) and Flexion (2014 IPO), and was the COO of Okairos where he led the process that culminated in the acquisition by GSK. Since being promoted to Managing Director in 2014, Tom has had lead roles in several investments including Crispr (2016 IPO), Audentes (2016 IPO), Annapurna (merged to form Adverum), Gritstone (2018 IPO), Crinetics (2018 IPO), Anokion, Therachon, Vividion, Tempest, Aligos, CODA and Passage.


Prior to joining Versant, Tom was a medicinal chemist at XenoPort, a start-up biotech company that completed an IPO in 2005. Tom earned his Ph.D. in chemistry from Stanford University.

Getting in touch


Ridgeline Therapeutics GmbH
A Versant Ventures Discovery Engine

Aeschenvorstadt 36

CH 4051 Basel


Offices  and Labs

Ridgeline Therapeutics GmbH
Hochbergerstrasse 60C
CH 4057 Basel

A Versant Ventures Discovery Engine.




Imprint  /  Privacy Policy  /  Terms of Use

© 2018 Ridgeline Therapeutics GmbH,
Ridgeline Discovery GmbH